588 Appendices 626. Itoh A, Iwase K, Jimbo S, Yamamoto H, Yamamoto N, Kokubo M, et al. Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. World journal of surgery. 2010;34:242-248. https://doi.org/10.1007/s00268-009-0344-4. 627. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 2000;60:4010-4015. 628. Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, et al. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. The Journal of clinical endocrinology and metabolism. 2005;90:328-334. https://doi.org/10.1210/jc.2004-0779. 629. Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer. 2014;83:197-204. https://doi.org/10.1016/j. lungcan.2013.11.025. 630. Qichang W, Lin B, Gege Z, Youjia Z, Qingjie M, Renjie W, et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. European journal of endocrinology. 2019;181:93-102. https://doi.org/10.1530/EJE-19-0261. 631. Kollecker I, von Wasielewski R, Langner C, Muller JA, Spitzweg C, Kreipe H, et al. Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues. Thyroid. 2012;22:529-535. https://doi.org/10.1089/thy.2011.0311. 632. Kim S, Chung JK, Min HS, Kang JH, Park DJ, Jeong JM, et al. Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nuclear medicine and molecular imaging. 2014;48:9197. https://doi.org/10.1007/s13139-013-0249-x. 633. Yoon M, Jung SJ, Kim TH, Ha TK, Urm SH, Park JS, et al. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Endocrine research. 2016;41:64-69. https://doi.org/10.3109/07435800.2015.1066803. 634. Kim BH, Kim IJ, Kim SS, Kim SJ, Lee CH, Kim YK. Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer. Cancer biotherapy & radiopharmaceuticals. 2010;25:309-315. https://doi.org/10.1089/cbr.2009.0636. 635. Lansoy-Kuhn C, Picquenot JM, Edet-Sanson A, Mechken F, Laberge-Le Couteulx S, Cornic M, et al. Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET/CT at recurrence in patients with welldifferentiated thyroid carcinoma. Nuclear medicine communications. 2013;34:340-346. https://doi.org/10.1097/ MNM.0b013e32835e59ee. 636. Ciampi R, Vivaldi A, Romei C, Del Guerra A, Salvadori P, Cosci B, et al. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol. 2008;291:5762. https://doi.org/10.1016/j.mce.2008.05.003. 637. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, et al. Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep. 2005;14:1499-1504. https://doi. org/10.3892/or.14.6.1499. 638. Mu N, Juhlin CC, Tani E, Sofiadis A, Reihner E, Zedenius J, et al. High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma. Endocrine. 2018;61:293-302. https://doi. org/10.1007/s12020-018-1627-z. 639. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987;8:138-140. 640. Demsar J, Curk T, Erjavec A, Gorup C, Hocevar T, Milutinovic M, et al. Orange: data mining toolbox in Python. Journal of Machine Learning Research. 2013;14:2349-2353. 641. Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid. 2004;14:806-812. https://doi.org/10.1089/thy.2004.14.806. 642. Lewy-Trenda I, Wierzchniewska-Lawska A. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors. Pol J Pathol. 2002;53:129-132. 643. Morari EC, Marcello MA, Guilhen AC, Cunha LL, Latuff P, Soares FA, et al. Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clinical endocrinology. 2011;75:247-254. https://doi.org/10.1111/j.13652265.2011.04032.x. 644. Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, et al. BRAF(V600E) mutation influences hypoxiainducible factor-1alpha expression levels in papillary thyroid cancer. Mod Pathol. 2010;23:1052-1060. https://doi. org/10.1038/modpathol.2010.86. 645. Prante O, Maschauer S, Fremont V, Reinfelder J, Stoehr R, Szkudlinski M, et al. Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. Journal of nuclear medicine. 2009;50:13641370. https://doi.org/10.2967/jnumed.109.062331. 646. Morani F, Pagano L, Prodam F, Aimaretti G, Isidoro C. Loss of expression of the oncosuppressor PTEN in thyroid incidentalomas associates with GLUT1 plasmamembrane expression. Panminerva Med. 2012;54:59-63.
RkJQdWJsaXNoZXIy MTk4NDMw